Hennion & Walsh Asset Management Inc. Acquires Shares of 175,614 ARS Pharmaceuticals, Inc. $SPRY

Hennion & Walsh Asset Management Inc. acquired a new position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 175,614 shares of the company’s stock, valued at approximately $1,407,000. Hennion & Walsh Asset Management Inc. owned approximately 0.18% of ARS Pharmaceuticals at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Torren Management LLC bought a new position in ARS Pharmaceuticals in the fourth quarter worth about $32,000. Mirae Asset Global Investments Co. Ltd. boosted its position in ARS Pharmaceuticals by 25.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company’s stock valued at $56,000 after acquiring an additional 982 shares in the last quarter. Osaic Holdings Inc. boosted its position in ARS Pharmaceuticals by 52.8% during the 2nd quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock valued at $91,000 after acquiring an additional 1,803 shares in the last quarter. Osterweis Capital Management Inc. purchased a new position in shares of ARS Pharmaceuticals during the 4th quarter worth approximately $65,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of ARS Pharmaceuticals by 58.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,097 shares of the company’s stock worth $106,000 after acquiring an additional 2,245 shares during the period. Institutional investors own 68.16% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on SPRY. Wall Street Zen upgraded ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings raised ARS Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 1st. Cantor Fitzgerald increased their price objective on ARS Pharmaceuticals from $12.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 28th. Finally, Leerink Partners lowered their price objective on ARS Pharmaceuticals from $25.00 to $24.00 and set an “outperform” rating for the company in a research report on Thursday, June 25th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $28.20.

ARS Pharmaceuticals Price Performance

Shares of NASDAQ SPRY opened at $6.05 on Thursday. The company has a 50 day simple moving average of $7.69 and a two-hundred day simple moving average of $8.35. ARS Pharmaceuticals, Inc. has a fifty-two week low of $4.91 and a fifty-two week high of $16.65. The company has a market capitalization of $600.78 million, a price-to-earnings ratio of -3.01 and a beta of 0.98. The company has a debt-to-equity ratio of 2.79, a quick ratio of 4.77 and a current ratio of 4.94.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.08). ARS Pharmaceuticals had a negative return on equity of 153.61% and a negative net margin of 200.00%.The company had revenue of $22.68 million during the quarter, compared to analysts’ expectations of $22.20 million. Analysts expect that ARS Pharmaceuticals, Inc. will post -1.95 EPS for the current fiscal year.

Insider Buying and Selling at ARS Pharmaceuticals

In other news, insider Alexander A. Fitzpatrick sold 3,355 shares of the firm’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $10.00, for a total transaction of $33,550.00. Following the completion of the transaction, the insider directly owned 90,910 shares in the company, valued at $909,100. This trade represents a 3.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Karas sold 25,000 shares of the firm’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $10.00, for a total value of $250,000.00. Following the transaction, the insider owned 12,176 shares of the company’s stock, valued at $121,760. The trade was a 67.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 33.80% of the company’s stock.

More ARS Pharmaceuticals News

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Negative Sentiment: Levi & Korsinsky said the lawsuit alleges ARS Pharmaceuticals did not adequately disclose that CVS Caremark’s rigid formulary system could delay a neffy coverage decision until January 2027, potentially causing the product to miss the summer and back-to-school allergy seasons. Levi & Korsinsky lawsuit notice
• Negative Sentiment: Several firms, including Rosen, Kaplan Fox, Faruqi & Faruqi, Pomerantz, and Bronstein Gewirtz & Grossman, announced or promoted the filed securities class action covering investors who purchased ARS securities from March 9 through June 24, 2026. The allegations could increase legal costs, reputational pressure, and uncertainty around neffy’s commercial outlook. Rosen class action announcement Kaplan Fox class action notice
• Neutral Sentiment: October 5, 2026 is the deadline for investors to seek appointment as lead plaintiff. The notices are largely attorney solicitations and do not represent a court finding that ARS Pharmaceuticals violated securities laws; the company’s potential liability remains unresolved. Faruqi class action deadline
• Neutral Sentiment: A reported short-interest update showed zero shares and a zero-day days-to-cover ratio, but the figures appear anomalous and provide little useful evidence about investor positioning.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.